To the Editor: Bradbury and colleagues highlight some important challenges in managing Plasmodium vivax malaria when appropriate diagnostics and therapeutics are lacking.1
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- 1. Bradbury RS, Robertson G, Norton RE, Taylor-Robinson AW. Missing malaria? Potential obstacles to diagnosis and hypnozoite eradication. Med J Aust 2014; 201: 630-631. <MJA full text>
- 2. Knope KE, Doggett SL, Kurucz N, et al. Arboviral diseases and malaria in Australia, 2011–12: annual report of the National Arbovirus and Malaria Advisory Committee. Commun Dis Intell Q Rep 2014; 38: E122-E142.
- 3. Leder K, Torresi J, Brownstein JS, et al. Travel-associated illness trends and clusters, 2000–2010. Emerg Infect Dis 2013; 19: 1049-1073.
- 4. Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 1005-1070.
- 5. Betuela I, Rosanas-Urgell A, Kiniboro B, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1–5 years of age. J Infect Dis 2012; 206: 1771-1780.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.